BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $4507.T readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07214571-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:S-337395 readout (P2) · Shionogi $4507.T
DESCRIPTION:A Study of S-337395 in Symptomatic Nonhospitalized Adults With 
 Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to S
 evere Disease\n\nPrimary completion date: 2026-12-30 (estimated)\nPhase 2 
 · Infectious · Respiratory Syncytial Virus Infections\nEnrollment: 192 
 · Sites: 89\n\nPrimary completion = last participant's primary-endpoint d
 ata collected\; topline results usually follow weeks to months later. Spon
 sor-reported\, often an estimate. Not investment advice.\n\nhttps://trials
 onar.netlify.app/radar.html?nct=NCT07214571\nhttps://clinicaltrials.gov/st
 udy/NCT07214571
URL:https://datacutoff.com/radar.html?nct=NCT07214571
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06776432-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sivopixant readout (P2) · Shionogi $4507.T
DESCRIPTION:Safety and Efficacy Study of Sivopixant\, Acetazolamide and SAS
 S-001 in Sleep Apnea\n\nPrimary completion date: 2026-12-31 (estimated)\nO
 riginally planned: 2025-12 (+13.0 months)\nPhase 2 · Neuro · Sleep Apnea
 \nEnrollment: 60 · Sites: 9\n\nPrimary completion = last participant's pr
 imary-endpoint data collected\; topline results usually follow weeks to mo
 nths later. Sponsor-reported\, often an estimate. Not investment advice.\n
 \nhttps://datacutoff.com/radar.html?nct=NCT06776432\nhttps://clini
 caltrials.gov/study/NCT06776432
URL:https://datacutoff.com/radar.html?nct=NCT06776432
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07746544-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Secutrelvir readout (P3) · Shionogi $4507.T
DESCRIPTION:Study of Secutrelvir in Participants With COVID-19\n\nPrimary c
 ompletion date: 2027-07-31 (estimated)\nPhase 3 · Infectious · COVID-19\
 nEnrollment: 1200 · Sites: 1\n\nPrimary completion = last participant's p
 rimary-endpoint data collected\; topline results usually follow weeks to m
 onths later. Sponsor-reported\, often an estimate. Not investment advice.\
 n\nhttps://datacutoff.com/radar.html?nct=NCT07746544\nhttps://clin
 icaltrials.gov/study/NCT07746544
URL:https://datacutoff.com/radar.html?nct=NCT07746544
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123155-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270808
DTEND;VALUE=DATE:20270809
SUMMARY:S-606001 readout (P2) · Shionogi $4507.T
DESCRIPTION:Study of S-606001 as an Add-on to Enzyme Replacement Therapy (E
 RT) in Participants With Late-onset Pompe Disease (LOPD)\n\nPrimary comple
 tion date: 2027-08-08 (estimated)\nPhase 2 · Rare · Pompe Disease\nEnrol
 lment: 45 · Sites: 28\n\nPrimary completion = last participant's primary-
 endpoint data collected\; topline results usually follow weeks to months l
 ater. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttp
 s://trialsonar.netlify.app/radar.html?nct=NCT07123155\nhttps://clinicaltri
 als.gov/study/NCT07123155
URL:https://datacutoff.com/radar.html?nct=NCT07123155
CATEGORIES:Rare,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
